Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19

  1. Michael A. Thompson
  2. Jeffrey P. Henderson
  3. Pankil K. Shah
  4. Samuel M. Rubinstein
  5. Michael J. Joyner
  6. Toni K. Choueiri
  7. Daniel B. Flora
  8. Elizabeth A. Griffiths
  9. Anthony P. Gulati
  10. Clara Hwang
  11. Vadim S. Koshkin
  12. Esperanza B. Papadopoulos
  13. Elizabeth V. Robilotti
  14. Christopher T. Su
  15. Elizabeth M. Wulff-Burchfield
  16. Zhuoer Xie
  17. Peter Paul Yu
  18. Sanjay Mishra
  19. Jonathon W. Senefeld
  20. Dimpy P. Shah
  21. Jeremy L. Warner
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Convalescent plasma may benefit immunocompromised individuals with COVID-19, including those with hematologic malignancy. We evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic malignancy and COVID-19 from a multi-institutional cohort. 143 treated patients were compared to 823 untreated controls. After adjustment for potential confounding factors, convalescent plasma treatment was associated with improved 30-day mortality (hazard ratio, 0.60; 95% CI, 0.37-0.97). This association remained significant after propensity-score matching (hazard ratio, 0.52; 95% CI, 0.29-0.92). These findings suggest a potential survival benefit in the administration of convalescent plasma to patients with hematologic malignancy and COVID-19.

Related articles

Related articles are currently not available for this article.